Navigation Links
Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
Date:4/7/2009

DENVER, April 7 /PRNewswire/ -- Pharmatech Oncology, Inc., a Research Management Organization (RMO), has been selected as one of the presenting companies at the Company Showcase during BIOZONA 2009 - Arizona's Annual Bioscience Industry Conference at the Sheraton Phoenix Downtown on April 7th in Phoenix, Arizona.

Matthew B. Wiener, PharmD, COO and Founder of Pharmatech Oncology, will present during the first session of the conference. The presentation will cover topics including: the science, business and markets on which the company is based, recent accomplishments, and strategic partnerships.

Dr. Wiener will focus on the many accomplishments for Pharmatech Oncology in cancer clinical trials utilizing the Just-In-Time (JIT) enrollment methodology. The aim of the Just-In-Time program is to shorten the time to enroll cancer patients into clinical trials and also expand the number of patients being offered trials. "Pharmatech Oncology is honored to be selected from a large number of applicants to be one of eighteen companies presenting at this distinguished BIOZONA event. We anticipate great exposure for our Just-In-Time clinical trial program, as we feel it is revolutionizing the enrollment process of adult cancer patients into clinical trials," states Dr. Wiener. For further information about BIOZONA 2009, please visit the event web site at http://www.azbio.org/Biozona2009.asp.

About Pharmatech Oncology:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. With Data Management as a separate business entity, it allows for management of data for other types
'/>"/>

SOURCE Pharmatech Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
2. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
3. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
4. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
5. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
6. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
7. Pharmatech 2.0: Introducing Pharmatech Oncology
8. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
9. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
10. WuXi PharmaTech Announces Third Quarter 2008 Results
11. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... OncLive® is pleased ... at Thomas Jefferson University has joined its Strategic ... Alliance Partnership program, the Sidney Kimmel Cancer Center ... awareness of the Center’s cutting-edge research programs, comprehensive ... and other health care professionals from the Sidney ...
(Date:10/19/2014)... , Oct. 19, 2014 NextCODE Health, which enables ... genome in real time, today announced the launch of its ... Exchange , at the American Society of Human Genetics (ASHG) ... learn more, sign up and apply for free beta access, ... features and benefits can be viewed here . ...
(Date:10/19/2014)... 19, 2014 The Asian Orthopedic braces and ... Asia with analysis and forecast of revenue. The Orthopedic braces ... to around $416.5 million by 2018, at a developing CAGR ... TOC of the Asian Orthopedic braces and support systems market, ... also provides a glimpse of the segmentation of orthopedic braces ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4
... in Revenue and Positive ... EBITDA for Three Consecutive Quarters, PRINCETON, N.J., April 1 ... production company, today,announced record growth in revenues for 2007. The ... and generated positive EBITDA for,the third consecutive quarter. Laureate achieved ...
... FREMONT, Calif., April 1, 2008 WaferGen,Biosystems, ... developer of,state-of-the-art gene expression, genotyping, cell biology ... signing of an exclusive distribution,agreement for the ... in Germany. The distributor agreement covers WaferGen,s,entire ...
... 2008 Plethora Solutions Holdings PLC,("Plethora", AIM: PLE), ... management of urological disorders, today announced that it,has ... Paul Capital,Healthcare. Through this agreement, Plethora will receive ... payable upon signature and a further $10 million,upon ...
Cached Biology Technology:Laureate Pharma Reports Record Growth for 2007 2Laureate Pharma Reports Record Growth for 2007 3WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany 2WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany 3WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany 4WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany 5Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 2Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 3Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 4
(Date:10/18/2014)... a sample of patients with undiagnosed, suspected genetic conditions, ... with a higher molecular diagnostic yield than traditional molecular ... JAMA . The study is being released to coincide ... , Exome sequencing, which sequences the protein­coding region of ... material present in a cell or organism), has been ...
(Date:10/17/2014)... in German . ... day in order to reproduce? And why are there two ... the latest issue of the research journal Molecular Human ... Steven Ramm from Bielefeld University Bielefeld has compiled this special ... for a female to copulate with several males in quick ...
(Date:10/17/2014)... German . ... When treating overdoses, doctors are often limited to supportive therapy ... is a combination of drugs involved. So what can be ... grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute of ... to this question. "The task was to develop an agent ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... - Animals that choose to eat in the presence of a ... go into a defensive mode and pay a physical penalty for ... crop pest hornworm caterpillar, a study shows. While other animals ... hornworm caterpillars slow or stop eating but actually keep up their ...
... to participate in ELIXIR ( www.elixir-europe.org ), a major ... in Europe. With one of Europe,s larger economies now ... is well placed to continue its excellent progress. ... infrastructure for managing biological data to support research and ...
... the IRCM, led by geneticist Dr. Jacques Drouin, recently ... inflammation. This important breakthrough will be published in tomorrow,s ... . IRCM scientists study glucocorticoids, a class ... reduce inflammation. They are used in medicine to treat ...
Cached Biology News:Caterpillar gets more from its food when predator is on the prowl 2Italy pledges to be part of ELIXIR research infrastructure 2Controlling inflammatory and immune responses 2
Glycerokinase; from Bacillus stearothermophilus...
... The inductive drives of VARIOMAG Magnetic ... as motors, belts, or mechanical bearings, making ... In addition, the VARIOMAG inductive drive can ... water, dust or microorganisms. This is why ...
...
... FL is equipped with ... measurement technologies that complement ... advanced features of Fluoroskan ... Fluoroskan Ascent FL provides ...
Biology Products: